Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.

Inclusion Criteria:

• Type 2 diabetes for dapagliflozin arm
• Normal glucose tolerance (fasting plasma glucose <100 mgd/l, HbA1c <6.0%) for normal glucose tolerance arm
• Age 18 to 75 years
• BMI <35 kg/m2
• For type 2 diabetes patients, at least 3 months of treatment period and HbA1c 7.5 to 11.0% and treatment with lifestyle modification and/or metformin or sulfonylurea

Exclusion Criteria:

• Who is allergic to dapagliflozin
• Type 1 diabetes
• Patients with history of diabetic ketoacidosis
• Reduced renal function (eGFR <60ml/min/1.73m2)
• Taking loop diuretics or dehydrated patient
• History of hypotension when taking hypertensive medication
• Diagnosed with heart failure
• Diagnosed with cerebral infarction
• Taking insulin, DPP-4 inhibitor, GLP-1 analogue, pioglitazone, alpha-glucosidase inhibitor
• Above upper limit of normal hematocrit range (male 39-52%, female 36-48%)
• Pregnant or breastfeeding women
• History of recurrent genitourinary infection
• AST/ALT more than two fold increased above normal upper limit
• Hemolytic disorder